Crinetics Pharmaceuticals

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is dedicated to driving the next generation of endocrinology care, focusing on discovering, developing, and commercializing innovative therapies to improve the lives of patients with endocrine-related diseases. Their mission is to transform endocrine disease treatment as a premier global pharmaceutical company.

Products & Services

PALSONIFY™ (paltusotine):An oral SST2 agonist approved by the FDA for the first-line treatment of adults with acromegaly.

Atumelnant:An oral ACTH antagonist granted FDA Orphan Drug Designation for the treatment of Congenital Adrenal Hyperplasia (CAH).

CRN09682:A nonpeptide drug conjugate under development as part of their pipeline.

Specialties

Endocrinology Drug Discovery and Development Therapeutic Innovation for Endocrine Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: approximately $350 million FAN: 350000000	D: 2026-01-06 FD: 2026-01-06	6 investors
2	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: $350.0 million FAN: 350000000	D: 2026-01-05 FD: 2026-01-05	5 investors
3	RT: Public Offering T: - FT: Public Offering	A: 400000000 MR: - FA: 400.0 million FAN: 400000000	D: 2024-10-08 FD: 2024-10-08	2 investors
4	RT: Public Offering T: - FT: Public Offering	A: 500000000 MR: - FA: $500.0 million FAN: 500000000	D: 2024-10-08 FD: 2024-10-08	9 investors
5	RT: Private Placement T: - FT: Private Placement	A: 350000000 MR: - FA: $350 million FAN: 350000000	D: 2024-02-28 FD: 2024-02-28	11 investors

Public Offering Latest

2026-01-06

$350.0M

6 investors (Pro only)

Public Offering 2026-01-05

$350.0M

Public Offering 2024-10-08

$400.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Ashley

Patient with Neuroendocrine Tumors

R

R. Scott Struthers, Ph.D.

Co-Founder and Chief Executive Officer

S

Stephen F. Betz

Co-Founder & Chief Scientific Officer

G

Garlan Adams

Chief Legal Officer

A

Adriana C. Cabré

Chief Human Resources Officer

O

Omar Hamdy

Chief of Staff & Head of Portfolio Strategy

View 33 more team members with Pro

Unlock Full Team Directory

Recent News